Something in the air: hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapy.
Level 5 - mechanism / opinion, no new human data
Commentary on basic/translational research with no original clinical data
PubMed 25873169 · doi:10.1016/j.ccell.2015.03.014
What was done
This publication is an editorial commentary discussing a study by Hatfield and colleagues published in Science Translational Medicine, which investigated supplemental oxygen as a method to modify the tumor microenvironment.
What was found
The abstract reports no original experimental data or quantitative figures. It summarizes the finding that supplemental oxygen can act as an immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway.
Why it matters
It highlights a potential physiological approach to modifying the tumor microenvironment to improve the efficacy of existing immune checkpoint blockade therapies.
Limits
This is a brief commentary containing no primary data, clinical trials, or quantitative outcomes. Findings discussed are from an external preclinical paper.
Cited by
- context Hyperoxygenation enhances T-cell metabolism and infiltration, reduces PD-L1 expression, and improves the efficacy of immune checkpoint inhibitor therapy.